Research output: Contribution to journal › Review article › peer-review
Hatem A.F.M. Hassan, Sandra S. Diebold, Lesley A. Smyth, Adam A. Walters, Giovanna Lombardi, Khuloud T. Al-Jamal
Original language | English |
---|---|
Pages (from-to) | 79-90 |
Number of pages | 12 |
Journal | Journal of Controlled Release |
Volume | 297 |
DOIs | |
Published | 10 Mar 2019 |
Additional links |
Hassan_et_al_JCR_2019.pdf, 765 KB, application/pdf
Uploaded date:12 Mar 2020
Version:Accepted author manuscript
Licence:CC BY-NC-ND
Tumour−specific, immuno−based therapeutic interventions can be considered as safe and effective approaches for cancer therapy. Exploitation of nano−vaccinology to intensify the cancer vaccine potency may overcome the need for administration of high vaccine doses or additional adjuvants and therefore could be a more efficient approach. Carbon nanotube (CNT) can be described as carbon sheet(s) rolled up into a cylinder that is nanometers wide and nanometers to micrometers long. Stemming from the observed capacities of CNTs to enter various types of cells via diversified mechanisms utilising energy−dependent and/or passive routes of cell uptake, the use of CNTs for the delivery of therapeutic agents has drawn increasing interests over the last decade. Here we review the previous studies that demonstrated the possible benefits of these cylindrical nano−vectors as cancer vaccine delivery systems as well as the obstacles their clinical application is facing.
King's College London - Homepage
© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454